A Double-blind,Randomized, Placebo-controlled Study to Assess Exercise Tolerance After Iron Repletion With Ferric Derisomaltose (Monoferric®) IV Compared to Placebo in Heart Failure With Preserved Ejection Fraction and With Iron Deficiency
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms IRONMET-HFpEF
- 28 Jun 2022 Planned End Date changed from 1 Apr 2025 to 31 Mar 2025.
- 28 Jun 2022 Planned primary completion date changed from 1 Jan 2025 to 28 Feb 2025.
- 18 Mar 2022 Status changed from not yet recruiting to recruiting.